ONCOVIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONCOVIN (vincristine) is a vinca alkaloid small-molecule injectable chemotherapy agent approved in 1963 for oncology indications. The drug works by disrupting microtubule dynamics to arrest cell division, making it a foundational agent in combination chemotherapy regimens. It is administered intravenously and remains a standard component of multi-drug cancer protocols.
LOE Approaching
As a legacy chemotherapy agent approaching loss of exclusivity with moderate competitive pressure (30/100), the commercial team is likely contracting and focused on operational efficiency and managed care retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome
Started Apr 2011
43 enrolled
Richter's Syndrome
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
Started Jul 2007
787 enrolled
B-cell Lymphoma
Career Relevance
ONCOVIN represents a career opportunity primarily in late-stage asset management, managed care negotiation, and operational efficiency rather than growth or innovation roles. Working on this product offers exposure to legacy brand stewardship and defending market position against generics in a complex oncology landscape.
Worked on ONCOVIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.